Published in J Cell Mol Med on August 01, 2009
Cross-talk between calcineurin/NFAT and Jak/STAT signalling induces cardioprotective alphaB-crystallin gene expression in response to hypertrophic stimuli. J Cell Mol Med (2009) 0.91
Cardiomyocyte-specific overexpression of HEXIM1 prevents right ventricular hypertrophy in hypoxia-induced pulmonary hypertension in mice. PLoS One (2012) 0.82
Small interfering RNA targeting PGC-1α inhibits VEGF expression and tube formation in human retinal vascular endothelial cells. Int J Ophthalmol (2015) 0.75
Functional Interaction between HEXIM and Hedgehog Signaling during Drosophila Wing Development. PLoS One (2016) 0.75
HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab (2006) 13.22
HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metab (2006) 10.14
Controlling the elongation phase of transcription with P-TEFb. Mol Cell (2006) 9.95
Recruitment of P-TEFb for stimulation of transcriptional elongation by the bromodomain protein Brd4. Mol Cell (2005) 8.92
PGC-1 coactivators: inducible regulators of energy metabolism in health and disease. J Clin Invest (2006) 6.85
Peroxisome proliferator-activated receptor gamma coactivator 1 coactivators, energy homeostasis, and metabolism. Endocr Rev (2006) 6.68
The 7SK small nuclear RNA inhibits the CDK9/cyclin T1 kinase to control transcription. Nature (2001) 5.14
Inhibition of P-TEFb (CDK9/Cyclin T) kinase and RNA polymerase II transcription by the coordinated actions of HEXIM1 and 7SK snRNA. Mol Cell (2003) 4.27
Mitochondrial dysfunction resulting from loss of cytochrome c impairs cellular oxygen sensing and hypoxic HIF-alpha activation. Cell Metab (2005) 3.94
Hypoxia-inducible factor 1: oxygen homeostasis and disease pathophysiology. Trends Mol Med (2001) 3.87
The Yin and Yang of P-TEFb regulation: implications for human immunodeficiency virus gene expression and global control of cell growth and differentiation. Microbiol Mol Biol Rev (2006) 3.44
Activation and function of cyclin T-Cdk9 (positive transcription elongation factor-b) in cardiac muscle-cell hypertrophy. Nat Med (2002) 2.82
Phosphorylated positive transcription elongation factor b (P-TEFb) is tagged for inhibition through association with 7SK snRNA. J Biol Chem (2003) 2.21
Consequences of brief ischemia: stunning, preconditioning, and their clinical implications: part 1. Circulation (2001) 2.06
Modulation of a P-TEFb functional equilibrium for the global control of cell growth and differentiation. Mol Cell Biol (2006) 1.99
Preconditioning: a paradigm shift in the biology of myocardial ischemia. Am J Physiol Heart Circ Physiol (2006) 1.88
Activation of cardiac Cdk9 represses PGC-1 and confers a predisposition to heart failure. EMBO J (2004) 1.62
Regulating the regulator: NF-kappaB signaling in heart. J Mol Cell Cardiol (2006) 1.57
Into the heart: the emerging role of the ubiquitin-proteasome system. J Mol Cell Cardiol (2006) 1.35
Increase of SUMO-1 expression in response to hypoxia: direct interaction with HIF-1alpha in adult mouse brain and heart in vivo. FEBS Lett (2004) 1.34
Mitochondrial reactive oxygen species are required for hypoxic HIF alpha stabilization. Adv Exp Med Biol (2006) 1.32
Ablation of the CLP-1 gene leads to down-regulation of the HAND1 gene and abnormality of the left ventricle of the heart and fetal death. Mech Dev (2004) 1.32
JAK/STAT signaling is associated with cardiac dysfunction during ischemia and reperfusion. Circulation (2001) 1.30
HEXIM1 and the control of transcription elongation: from cancer and inflammation to AIDS and cardiac hypertrophy. Cell Cycle (2007) 1.22
Translation of ischemic preconditioning to the patient: prolyl hydroxylase inhibition and hypoxia inducible factor-1 as novel targets for stroke therapy. Stroke (2004) 1.21
Thioredoxin and ventricular remodeling. J Mol Cell Cardiol (2006) 1.14
Mitochondrial regulation of oxygen sensing. Mitochondrion (2005) 1.12
Mechanisms controlling CDK9 activity. Front Biosci (2006) 1.11
Ménage-à-trois 1 is critical for the transcriptional function of PPARgamma coactivator 1. Cell Metab (2007) 1.00
Cyclins that don't cycle--cyclin T/cyclin-dependent kinase-9 determines cardiac muscle cell size. Cell Cycle (2003) 0.97
Pivotal role of cardiac lineage protein-1 (CLP-1) in transcriptional elongation factor P-TEFb complex formation in cardiac hypertrophy. Cardiovasc Res (2007) 0.96
Conversion of death signal into survival signal by redox signaling. Biochemistry (Mosc) (2004) 0.89
JAK-STAT pathway in cardiac ischemic stress. Vascul Pharmacol (2005) 0.84
Identification of regulated genes during transient cortical ischemia in mice by restriction-mediated differential display (RMDD). Brain Res Mol Brain Res (2004) 0.80
Angiogenic signal triggered by ischemic stress induces myocardial repair in rat during chronic infarction. J Mol Cell Cardiol (2004) 1.93
Resveratrol alleviates cardiac dysfunction in streptozotocin-induced diabetes: Role of nitric oxide, thioredoxin, and heme oxygenase. Free Radic Biol Med (2007) 1.90
Retracted Targeted disruption of peroxiredoxin 6 gene renders the heart vulnerable to ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol (2006) 1.77
What is new for an old molecule? Systematic review and recommendations on the use of resveratrol. PLoS One (2011) 1.74
Potentiation of a survival signal in the ischemic heart by resveratrol through p38 mitogen-activated protein kinase/mitogen- and stress-activated protein kinase 1/cAMP response element-binding protein signaling. J Pharmacol Exp Ther (2006) 1.71
Retracted Redox regulation of angiotensin II preconditioning of the myocardium requires MAP kinase signaling. J Mol Cell Cardiol (2006) 1.70
Anti-inflammatory responses of resveratrol. Inflamm Allergy Drug Targets (2007) 1.63
Resveratrol-mediated activation of cAMP response element-binding protein through adenosine A3 receptor by Akt-dependent and -independent pathways. J Pharmacol Exp Ther (2005) 1.62
Role of Akt signaling in mitochondrial survival pathway triggered by hypoxic preconditioning. Circulation (2004) 1.58
Alcohol in moderation, cardioprotection, and neuroprotection: epidemiological considerations and mechanistic studies. Alcohol Clin Exp Res (2008) 1.55
Cardioprotection by adaptation to ischaemia augments autophagy in association with BAG-1 protein. J Cell Mol Med (2008) 1.54
Molecular mechanisms of cardioprotection by a novel grape seed proanthocyanidin extract. Mutat Res (2003) 1.53
Retracted Differential proteomic profiling to study the mechanism of cardiac pharmacological preconditioning by resveratrol. J Cell Mol Med (2006) 1.50
Retracted Caveolin and MAP kinase interaction in angiotensin II preconditioning of the myocardium. J Cell Mol Med (2007) 1.48
Redox signaling in vascular angiogenesis. Free Radic Biol Med (2002) 1.45
Oxidized and ubiquitinated proteins may predict recovery of postischemic cardiac function: essential role of the proteasome. Antioxid Redox Signal (2005) 1.40
Cardioprotection by resveratrol: a novel mechanism via autophagy involving the mTORC2 pathway. Cardiovasc Res (2009) 1.40
Grapes, wines, resveratrol, and heart health. J Cardiovasc Pharmacol (2009) 1.32
Ablation of the CLP-1 gene leads to down-regulation of the HAND1 gene and abnormality of the left ventricle of the heart and fetal death. Mech Dev (2004) 1.32
Resveratrol and chemoprevention. Cancer Lett (2009) 1.31
Retracted Resveratrol, a unique phytoalexin present in red wine, delivers either survival signal or death signal to the ischemic myocardium depending on dose. J Nutr Biochem (2008) 1.31
Autophagy, redox signaling, and ventricular remodeling. Antioxid Redox Signal (2009) 1.28
Mechanical regulation of the proangiogenic factor CCN1/CYR61 gene requires the combined activities of MRTF-A and CREB-binding protein histone acetyltransferase. J Biol Chem (2009) 1.28
Grape seed proanthocyanidins improved cardiac recovery during reperfusion after ischemia in isolated rat hearts. Am J Clin Nutr (2002) 1.26
Resveratrol: a therapeutic promise for cardiovascular diseases. Recent Pat Cardiovasc Drug Discov (2007) 1.24
Molecular mechanism of preconditioning. IUBMB Life (2008) 1.23
Retracted Expression of the longevity proteins by both red and white wines and their cardioprotective components, resveratrol, tyrosol, and hydroxytyrosol. Free Radic Biol Med (2008) 1.22
Sildenafil-mediated neovascularization and protection against myocardial ischaemia reperfusion injury in rats: role of VEGF/angiopoietin-1. J Cell Mol Med (2008) 1.21
Cardioprotection by endoplasmic reticulum stress-induced autophagy. Antioxid Redox Signal (2011) 1.21
Restoration of altered microRNA expression in the ischemic heart with resveratrol. PLoS One (2010) 1.17
Coordinated induction of iNOS-VEGF-KDR-eNOS after resveratrol consumption: a potential mechanism for resveratrol preconditioning of the heart. Vascul Pharmacol (2005) 1.16
Signal transduction in early heart development (II): ventricular chamber specification, trabeculation, and heart valve formation. Exp Biol Med (Maywood) (2007) 1.16
Thioredoxin redox signaling in the ischemic heart: an insight with transgenic mice overexpressing Trx1. J Mol Cell Cardiol (2003) 1.13
Retracted Pharmacological preconditioning with resveratrol: role of nitric oxide. Am J Physiol Heart Circ Physiol (2002) 1.13
Positive transcription elongation factor b activity in compensatory myocardial hypertrophy is regulated by cardiac lineage protein-1. Circ Res (2009) 1.12
Resveratrol ameliorates myocardial damage by inducing vascular endothelial growth factor-angiogenesis and tyrosine kinase receptor Flk-1. Cell Biochem Biophys (2006) 1.12
Emerging potential of thioredoxin and thioredoxin interacting proteins in various disease conditions. Biochim Biophys Acta (2008) 1.11
Dose-dependency of resveratrol in providing health benefits. Dose Response (2010) 1.11
Redox regulation of ischemic preconditioning is mediated by the differential activation of caveolins and their association with eNOS and GLUT-4. Am J Physiol Heart Circ Physiol (2007) 1.11
Prevention of concentric hypertrophy and diastolic impairment in aortic-banded rats treated with resveratrol. Am J Physiol Heart Circ Physiol (2007) 1.10
Resveratrol in cardiovascular health and disease. Ann N Y Acad Sci (2011) 1.10
Retracted Cardioprotective effect of resveratrol via HO-1 expression involves p38 map kinase and PI-3-kinase signaling, but does not involve NFkappaB. Free Radic Res (2006) 1.09
Pharmacological preconditioning with resveratrol: role of CREB-dependent Bcl-2 signaling via adenosine A3 receptor activation. Am J Physiol Heart Circ Physiol (2004) 1.09
Redox regulation of cell survival by the thioredoxin superfamily: an implication of redox gene therapy in the heart. Antioxid Redox Signal (2009) 1.08
Retracted Cardioprotection with palm tocotrienol: antioxidant activity of tocotrienol is linked with its ability to stabilize proteasomes. Am J Physiol Heart Circ Physiol (2005) 1.08
GATA-4 regulation of myocardial survival in the preconditioned heart. J Mol Cell Cardiol (2004) 1.08
Heme oxygenase-1-related carbon monoxide production and ventricular fibrillation in isolated ischemic/reperfused mouse myocardium. FASEB J (2003) 1.08
Structure, expression, and functional characterization of the mouse CLP-1 gene. Gene (2002) 1.07
STAT signaling in ischemic heart: a role of STAT5A in ischemic preconditioning. Am J Physiol Heart Circ Physiol (2003) 1.07
Pharmacological preconditioning with resveratrol: an insight with iNOS knockout mice. Am J Physiol Heart Circ Physiol (2002) 1.06
Cardioprotection with alcohol: role of both alcohol and polyphenolic antioxidants. Ann N Y Acad Sci (2002) 1.05
Retracted Cardioprotection with palm oil tocotrienols: comparision of different isomers. Am J Physiol Heart Circ Physiol (2007) 1.05
Retracted Ischemic preconditioning involves dual cardio-protective axes with p38MAPK as upstream target. J Mol Cell Cardiol (2007) 1.03
MK2-/- gene knockout mouse hearts carry anti-apoptotic signal and are resistant to ischemia reperfusion injury. J Mol Cell Cardiol (2004) 1.03
Protective mechanisms of resveratrol against ischemia-reperfusion-induced damage in hearts obtained from Zucker obese rats: the role of GLUT-4 and endothelin. Am J Physiol Heart Circ Physiol (2007) 1.01
BAG-1 induces autophagy for cardiac cell survival. Autophagy (2009) 1.00
Inhibition of Jak2 phosphorylation attenuates pressure overload cardiac hypertrophy. Vascul Pharmacol (2006) 0.98
Modified resveratrol Longevinex improves endothelial function in adults with metabolic syndrome receiving standard treatment. Nutr Res (2011) 0.97
Retracted Overexpression of glutaredoxin-2 reduces myocardial cell death by preventing both apoptosis and necrosis. J Mol Cell Cardiol (2007) 0.96
Pivotal role of cardiac lineage protein-1 (CLP-1) in transcriptional elongation factor P-TEFb complex formation in cardiac hypertrophy. Cardiovasc Res (2007) 0.96
Retracted Broccoli: a unique vegetable that protects mammalian hearts through the redox cycling of the thioredoxin superfamily. J Agric Food Chem (2007) 0.96
Hormetic response of resveratrol against cardioprotection. Exp Clin Cardiol (2010) 0.95
Potential candidates for ischemic preconditioning-associated vascular growth pathways revealed by antibody array. Am J Physiol Heart Circ Physiol (2005) 0.95
Retracted Does white wine qualify for French paradox? Comparison of the cardioprotective effects of red and white wines and their constituents: resveratrol, tyrosol, and hydroxytyrosol. J Agric Food Chem (2008) 0.94
Cardioprotection with alpha-tocopheryl phosphate: amelioration of myocardial ischemia reperfusion injury is linked with its ability to generate a survival signal through Akt activation. Biochim Biophys Acta (2008) 0.94
Role of lipid rafts in ceramide and nitric oxide signaling in the ischemic and preconditioned hearts. J Mol Cell Cardiol (2005) 0.94
Resveratrol and cardiovascular health. Mol Aspects Med (2010) 0.94
Retracted Redox regulation of resveratrol-mediated switching of death signal into survival signal. Free Radic Biol Med (2007) 0.94
Effects of L-carnitine and its derivatives on postischemic cardiac function, ventricular fibrillation and necrotic and apoptotic cardiomyocyte death in isolated rat hearts. Mol Cell Biochem (2003) 0.94
Co-ordinated autophagy with resveratrol and γ-tocotrienol confers synergetic cardioprotection. J Cell Mol Med (2010) 0.94
Regeneration of infarcted myocardium with resveratrol-modified cardiac stem cells. J Cell Mol Med (2012) 0.92
Signal transduction in early heart development (I): cardiogenic induction and heart tube formation. Exp Biol Med (Maywood) (2007) 0.92
Retracted Ischemic preconditioning triggers nuclear translocation of thioredoxin and its interaction with Ref-1 potentiating a survival signal through the PI-3-kinase-Akt pathway. Antioxid Redox Signal (2006) 0.92
Hypoxic preconditioning triggers myocardial angiogenesis: a novel approach to enhance contractile functional reserve in rat with myocardial infarction. J Mol Cell Cardiol (2002) 0.92
Retracted Role of glutaredoxin-1 in cardioprotection: an insight with Glrx1 transgenic and knockout animals. J Mol Cell Cardiol (2007) 0.91
Role of ceramide in ischemic preconditioning. J Am Coll Surg (2004) 0.91
Cross-talk between calcineurin/NFAT and Jak/STAT signalling induces cardioprotective alphaB-crystallin gene expression in response to hypertrophic stimuli. J Cell Mol Med (2009) 0.91
Cardiac lineage protein-1 (CLP-1) regulates cardiac remodeling via transcriptional modulation of diverse hypertrophic and fibrotic responses and angiotensin II-transforming growth factor β (TGF-β1) signaling axis. J Biol Chem (2012) 0.90
Physiological effects of resveratrol. Biofactors (2010) 0.90
The biological responses to resveratrol and other polyphenols from alcoholic beverages. Alcohol Clin Exp Res (2009) 0.90
MicroRNA signatures of resveratrol in the ischemic heart. Ann N Y Acad Sci (2011) 0.90
Retracted Protection against myocardial ischemia-reperfusion injury by the angiogenic Masterswitch protein PR 39 gene therapy: the roles of HIF1alpha stabilization and FGFR1 signaling. Antioxid Redox Signal (2007) 0.90
Oxidative injury induces selective rather than global inhibition of proteasomal activity. J Mol Cell Cardiol (2007) 0.90
Autophagy in the myocardium: Dying for survival? Exp Clin Cardiol (2006) 0.89
Lipid raft in cardiac health and disease. Curr Cardiol Rev (2009) 0.89
Redox activation of Ref-1 potentiates cell survival following myocardial ischemia reperfusion injury. Free Radic Biol Med (2007) 0.89
Cardioprotection with grapes. J Cardiovasc Pharmacol (2002) 0.89
Role of reactive oxygen species in the development of cytotoxicity with various forms of chewing tobacco and pan masala. Toxicology (2002) 0.89
Red wine antioxidant resveratrol-modified cardiac stem cells regenerate infarcted myocardium. J Cell Mol Med (2010) 0.88
Resveratrol, a component of wine and grapes, in the prevention of kidney disease. Ann N Y Acad Sci (2002) 0.88
Effects of Longevinex (modified resveratrol) on cardioprotection and its mechanisms of action. Can J Physiol Pharmacol (2010) 0.88
Caveolin and proteasome in tocotrienol mediated myocardial protection. Cell Physiol Biochem (2008) 0.88
Angiotensin preconditioning of the heart: evidence for redox signaling. Cell Biochem Biophys (2006) 0.87
Essential role of lipid raft in ischemic preconditioning. Cell Physiol Biochem (2008) 0.87
Generation of survival signal by differential interaction of p38MAPKalpha and p38MAPKbeta with caveolin-1 and caveolin-3 in the adapted heart. J Mol Cell Cardiol (2006) 0.87
Caveolae, caveolin, and cavins: potential targets for the treatment of cardiac disease. Ann Med (2011) 0.87
Longevity nutrients resveratrol, wines and grapes. Genes Nutr (2009) 0.87
Tocotrienols confer resistance to ischemia in hypercholesterolemic hearts: insight with genomics. Mol Cell Biochem (2011) 0.87
HFE mutation and dietary iron content interact to increase ischemia/reperfusion injury of the heart in mice. Circ Res (2003) 0.86